TABLE 1.
Characteristics of patients with NVAF prescribed a NOAC (July 2009 to June 2017)
| Characteristic | Apixaban | Dabigatran | Rivaroxaban |
|---|---|---|---|
| N = 2153 | N = 3089 | N = 5286 | |
| Mean age (SD), y | 78.5 (11.0) | 76.5 (11.0) | 76.0 (11.0) |
| Males | 1206 (56.0) | 1696 (54.9) | 3117 (59.0) |
| Anticoagulant naïve | 1517 (70.5) | 1999 (64.7) | 3480 (65.8) |
| Number of PCP visits | |||
| <3 | 546 (25.4) | 829 (26.8) | 1280 (24.2) |
| 4‐9 | 303 (14.1) | 496 (16.1) | 780 (14.8) |
| 10‐19 | 708 (32.9) | 1002 (32.4) | 1768 (33.4) |
| 20‐29 | 338 (15.7) | 459 (14.9) | 855 (16.2) |
| ≥30 | 258 (12.0) | 303 (9.8) | 603 (11.4) |
| Cardiovascular comorbidities a | |||
| Hypertension | 1724 (80.1) | 2533 (82.0) | 4359 (82.5) |
| Ischaemic stroke | 150 (7.0) | 300 (9.7) | 395 (7.5) |
| Myocardial infarction | 96 (4.5) | 119 (3.9) | 274 (5.2) |
| Heart failure | 683 (31.7) | 1115 (36.1) | 2010 (38.0) |
| VTE | 55 (2.5) | 107 (3.5) | 334 (6.3) |
| Haemorrhagic stroke | 9 (0.4) | 20 (0.6) | 33 (0.6) |
| Other comorbidities b | |||
| COPD | 320 (14.9) | 456 (14.8) | 870 (16.5) |
| Diabetes mellitus | 432 (20.1) | 710 (23.0) | 1161 (22.0) |
| Gastrointestinal bleeding | 81 (3.8) | 25 (0.8) | 195 (3.7) |
| Severe renal failure | 350 (16.3) | 452 (14.6) | 831 (15.7) |
| Cancer | 138 (6.4) | 190 (6.2) | 347 (6.6) |
Note: Data are n (%) unless otherwise specified.
Abbreviations: COPD, chronic obstructive pulmonary disease; NOAC, non‐vitamin K antagonist oral anticoagulant; NVAF, nonvalvular atrial fibrillation; PCP, primary care practitioner; VTE, venous thromboembolism.
a
In the year before the index date.
b
On the index date or in the year before the index date.